Contineum Therapeutics Is A Clinical Stage Biopharmaceutical Company Based In San Diegocaliforniafounded In 2009The Company Focuses On Developing Novel Oral Small Molecule Therapies For Neuroscienceinflammationand Immunology Indicationsit Aims To Create Precision Small Molecules That Can Alter The Course Of Clinical Impairment In These Areas The Company Has A Robust Pipeline Of Drug Candidates Currently In Clinical Trialsnotable Products Include Pipe 791Which Targets Idiopathic Pulmonary Fibrosisprogressive Multiple Sclerosisand Chronic Painpipe 307A Selective Inhibitor For Relapsing Remitting Multiple Sclerosis And Major Depressive Disorderand Ctx 343A Peripherally Restricted Antagonistcontineum Therapeutics Went Public In April 2024 And Is Led By Ceo Carmine Stengonethe Company Actively Engages With Investors And Participates In Industry Forums To Share Its Clinical Development Milestones
